Tagged with Switzerland

Switzerland From humble beginnings in southern Switzerland to crossing the USD 1 billion revenue mark, IBSA has quietly redefined what it means to grow a pharmaceutical company, without fanfare, without mega-mergers, and without compromising its values. In this interview, Chief Commercial Officer & Chairman of the Executive Committee Luca Crippa unpacks…

Switzerland As global science faces mounting complexity, the Paul Scherrer Institute (PSI) stands out as a model of long-term vision, technical excellence, and interdisciplinary ambition. Director Christian Rüegg discusses how PSI is advancing the frontiers of oncology, neuroscience, energy, and AI – developing radiopharmaceuticals and imaging entire neural networks, to enabling…

Switzerland Amid a crowded landscape of incremental innovation, Synendos Therapeutics stands out for its bold approach to neuropsychiatric drug development. Co-Founder and CEO Andrea Chicca shares how the company emerged from a translational research programme in Switzerland to pioneer a first-in-class therapeutic strategy targeting the endocannabinoid system, a master regulator of…

Switzerland Matthew Brabazon, General Manager of EMEA at SFI Health, a global natural healthcare company, discusses the company’s shift towards branded products and its focus on clinically supported products in the areas of cognition and the microbiome sector. What sets us apart is simple: our products are clinically substantiated. We walk…

Switzerland With the pharmaceutical landscape growing increasingly complex, few mid-sized players manage to carve out a distinct, resilient path. Rivopharm, a Swiss-headquartered generics manufacturer, is doing just that, expanding its direct presence across Europe, targeting technically demanding niche products, and balancing growth with operational precision. In this interview, CEO Piero Poli…

Switzerland What if the key to treating chronic and age-related diseases has been hidden in plain sight, within the 98 percent of the human genome once written off as “junk”? HAYA Therapeutics is betting on it. In this interview, CEO and Scientific Co-Founder Samir Ounzain reveals how his obsession with the…

Switzerland Susanne Caspar, CEO of Linnea SA, reflects on five years of growth and transformation at the Swiss botanical extract and API manufacturer. In this interview, Caspar shares insights on navigating the global cannabis market and on building a sustainable company culture  We believe the future is bright…Cannabis is growing at…

Switzerland Patrick Amstutz co-founded Molecular Partners 20 years ago with a vision to revolutionize medicine through protein engineering. Inspired by the potential of DARPins, a novel class of custom-built protein drugs, he has led the company through key milestones—including breakthroughs in ophthalmology, infectious diseases, and oncology. Today, Molecular Partners focuses on…

Switzerland Alentis Therapeutics, under the leadership of its CEO Roberto Iacone, has made significant strides in advancing innovative therapies targeting Claudin-1, a protein critical in inflammation and cancer. The company’s pipeline includes promising antibody-drug conjugates (ADCs), such as ALE.P02, currently in a Phase I/II clinical trial, and ALE.P03, expected to enter…

Switzerland Switzerland has long been recognised as a centre of scientific excellence, and in the field of Advanced Therapy Medicinal Products (ATMPs), it is quickly becoming a regulatory trailblazer. In this in-depth conversation, Julia Djonova, Head of ATMPs at Swissmedic, shares how the agency is positioning itself at the forefront of…

Switzerland Juergen Nelis, CEO of BGG World Holding, discusses the company’s strategic growth and evolving approach to sustainability, market expansion, and product innovation. He highlights key initiatives such as expanding production capabilities outside of China and refining BGG’s global leadership structure, while also addressing the challenges posed by geopolitical factors and…

Global Radioligand therapy (RLT), a specialized type of radiopharmaceutical therapy (RPT) that targets markers on tumor cells, is becoming a cancer treatment game changer. With a first FDA approval for Novartis’ Pluvicto, RLT has proved its potential. But are current regulatory frameworks and healthcare systems prepared to integrate this less-than-typical therapy?…